Vyvgart® Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) – New indication
June 21, 2024 - argenx announced the FDA approval of Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc), for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Download PDF
